Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

The Conversation

How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks

In some cases, biotechs go public without having even a single product on the market.

Investors Business Daily

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Top T. Rowe Price Fund Manager Shares Her Secrets

Stock picking is the hallmark of top mutual fund T. Rowe Price U.S. Equity Research Fund.

Investors Business Daily

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales

Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.

Investors Business Daily

Failure to Warn: The Type of Product Liability Ozempic is Being Sued for

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. Recently, it has been in the spotlight due to lawsuits being filed against its manufacturer, Novo Nordisk. These lawsuits claim that Ozempic has been linked to a serious gastrointestinal condition called gastroparesis.

inkl

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Roll Call

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Investors Business Daily

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review

The stock market rally revived with the major indexes reclaiming key levels and many top leaders flashing buy signals.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

StockNews.com

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Jumps After Weight-Loss Pill Tops Wegovy; Lilly, Viking Shares Rise

Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed Wegovy.

The Independent UK

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic maker sued over claims the weight-loss medication led to woman’s colon removal

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication

Investors Business Daily

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Inverse

Scientists Confirmed An Important Connection Between Semaglutide and Mental Health

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

Investors Business Daily

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

Investors Business Daily

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

1 … 3 4 5 6

People

Lars Fruergaard Jørgensen

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.